ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Cancer diagnostics company Biomoda, Inc. (OTC BB: BMOD) (www.biomoda.com) announced receipt of $244,479 in federal grant funding for its CyPath® diagnostic assay for the detection of early-stage lung cancer. The Internal Revenue Service issued the funding under the Qualifying Therapeutic Discovery Project administered under section 48D of the Internal Revenue Code.
